Novogen Ltd (NASDAQ:NVGN)

Data as of 2:45pm ET
 -0.1288 / -4.34%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Novogen Ltd. engages in the business of pharmaceutical drug development. The company's inaugural drug candidate CS-6 belongs to a new class of drug candidates known as Mitochondrial Electron Transfer Inhibitors that work by depriving the cancer cell of its main energy source. CS-6 is being developed in the first instance for the treatment of temozolomide-resistant glioblastoma multiforme, the main form of primary brain cancer, and for late-stage chemo-refractory ovarian cancer. Novogen was founded by Graham Edmund Kelly in March 1994 and is headquartered in Hornsby, Australia.

Contact Information

Novogen Ltd.
16-20 Edgeworth David Avenue
Hornsby New South Wales (nsw) 2077
P:(129) 476-0344
Investor Relations:



Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Graham Edmund KellyExecutive Chairman & Chief Executive Officer
Steven CoffeyChief Financial Officer & Non-Executive Director
David BrownChief Scientific Officer
Lionel MateoSecretary

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.